{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:20:42Z","timestamp":1786123242220,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1213\/ane.0b013e31819dcc51","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T17:56:14Z","timestamp":1242928574000},"page":"1803-1810","source":"Crossref","is-referenced-by-count":11,"title":["New Therapeutic Agents for Diabetes Mellitus: Implications for Anesthetic Management"],"prefix":"10.1213","volume":"108","author":[{"given":"Daniel","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Peterfreund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210902","first-page":"1420","article-title":"Anesthesiology.","author":"Peterfreund","year":"2007"},{"key":"R2-15-20210902","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bja\/85.1.80","article-title":"Anaesthetic management of patients with diabetes mellitus.","volume":"85","author":"McAnulty","year":"2000","journal-title":"Br J Anaesth"},{"key":"R3-15-20210902","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bpa.2004.05.012","article-title":"Strategies for managing the diabetic patient.","volume":"18","author":"Robertshaw","year":"2004","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"R4-15-20210902","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1213\/01.ane.0000167726.87731.af","article-title":"Perioperative management of pediatric surgical patients with diabetes mellitus.","volume":"101","author":"Rhodes","year":"2005","journal-title":"Anesth Analg"},{"key":"R5-15-20210902","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-15-20210902","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1463-1326.2007.00737.x","article-title":"Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes.","volume":"10","author":"Maggs","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"R8-15-20210902","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2515\/therapie:2007054","article-title":"Newly approved and promising antidiabetic agents.","volume":"62","author":"Combettes","year":"2007","journal-title":"Therapie"},{"key":"R9-15-20210902","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jcp.2006.043232","article-title":"Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.","volume":"61","author":"Ranganath","year":"2008","journal-title":"J Clin Pathol"},{"key":"R10-15-20210902","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"R11-15-20210902","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"R12-15-20210902","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1.","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"R13-15-20210902","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones.","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"R14-15-20210902","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"R15-15-20210902","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-15-20210902","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum.","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"R17-15-20210902","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7\u201336)amide is transformed to glucagon-like peptide-1-(9\u201336)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"key":"R18-15-20210902","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hcm081","article-title":"Gliptins: a new class of oral hypoglycaemic agent.","volume":"100","author":"Chahal","year":"2007","journal-title":"QJM"},{"key":"R19-15-20210902","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2013role in the inactivation of regulatory peptides.","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"R20-15-20210902","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.7903479","article-title":"T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells.","volume":"262","author":"Callebaut","year":"1993","journal-title":"Science"},{"key":"R21-15-20210902","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ijc.2910640508","article-title":"CD26 (dipeptidyl peptidase IV\/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma.","volume":"64","author":"Tanaka","year":"1995","journal-title":"Int J Cancer"},{"key":"R22-15-20210902","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/diacare.15.2.270","article-title":"Insulinotropic action of glucagonlike peptide-I-(7\u201337) in diabetic and nondiabetic subjects.","volume":"15","author":"Nathan","year":"1992","journal-title":"Diabetes Care"},{"key":"R23-15-20210902","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1345\/aph.1H060","article-title":"Exenatide: a new option for the treatment of type 2 diabetes.","volume":"40","author":"Yoo","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R24-15-20210902","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3949\/ccjm.73.5.477","article-title":"Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.","volume":"73","author":"Hoogwerf","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"R25-15-20210902","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3949\/ccjm.73.4.382","article-title":"New therapies for type 2 diabetes based on glucagon-like peptide 1.","volume":"73","author":"Salehi","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"R26-15-20210902","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1463-1326.2007.00705.x","article-title":"Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.","volume":"9","author":"Idris","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R27-15-20210902","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"issue":"Suppl 3","key":"R28-15-20210902","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes.","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"R29-15-20210902","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"R30-15-20210902","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy.","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"R31-15-20210902","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1213\/01.ane.0000263278.05423.a3","article-title":"The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors.","volume":"104","author":"Guindon","year":"2007","journal-title":"Anesth Analg"},{"key":"R32-15-20210902","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjp.0705334","article-title":"The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase.","volume":"139","author":"Patel","year":"2003","journal-title":"Br J Pharmacol"},{"key":"R33-15-20210902","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00000542-200602000-00012","article-title":"Effects of general anesthesia on anandamide blood levels in humans.","volume":"104","author":"Schelling","year":"2006","journal-title":"Anesthesiology"},{"issue":"Suppl 1","key":"R34-15-20210902","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2826.2008.01692.x","article-title":"The endocannabinoid system and the control of glucose homeostasis.","volume":"20","author":"Nogueiras","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"R35-15-20210902","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beem.2007.08.005","article-title":"Cannabinoid-1 receptor antagonists in type-2 diabetes.","volume":"21","author":"Scheen","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R36-15-20210902","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2007.06.011","article-title":"What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?","volume":"120","author":"Jensen","year":"2007","journal-title":"Am J Med"},{"key":"R37-15-20210902","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1124\/mol.106.033118","article-title":"Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.","volume":"71","author":"Bifulco","year":"2007","journal-title":"Mol Pharmacol"},{"key":"R38-15-20210902","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"R39-15-20210902","first-page":"250","article-title":"Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.","volume":"16","year":"2007","journal-title":"Prescrire Int"},{"key":"R40-15-20210902","first-page":"1460","article-title":"Panel advises against rimonabant approval.","volume":"64","author":"Traynor","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"R41-15-20210902","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"R42-15-20210902","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"R45-15-20210902","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"R46-15-20210902","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"}],"container-title":["Anesthesia & Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ane.0b013e31819dcc51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:12:15Z","timestamp":1786111935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-200906000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e31819dcc51","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}